A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma
Abstract Multiple myeloma (MM) is a heterogeneous haematological disease that remains clinically challenging. Increased activity of the epigenetic silencer EZH2 is a common feature in patients with poor prognosis. Previous findings have demonstrated that metabolic profiles can be sensitive markers f...
Main Authors: | Patrick Nylund, Alba Atienza Párraga, Jakob Haglöf, Elke De Bruyne, Eline Menu, Berta Garrido-Zabala, Anqi Ma, Jian Jin, Fredrik Öberg, Karin Vanderkerken, Antonia Kalushkova, Helena Jernberg-Wiklund |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-02-01
|
Series: | Cell Death and Disease |
Online Access: | https://doi.org/10.1038/s41419-021-03447-8 |
Similar Items
-
Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models
by: Jinsong Hu, et al.
Published: (2012-11-01) -
Targeting EZH2 in Multiple Myeloma—Multifaceted Anti-Tumor Activity
by: Mohammad Alzrigat, et al.
Published: (2018-09-01) -
Polycomb target genes are silenced in multiple myeloma.
by: Antonia Kalushkova, et al.
Published: (2010-07-01) -
Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma
by: Elke De Bruyne, et al.
Published: (2013-04-01) -
The Effects of Forodesine in Murine and Human Multiple Myeloma Cells
by: Liesbeth Bieghs, et al.
Published: (2010-01-01)